/
BIIB
$216.06-$0.57 (-0.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$31.9B
148M shares
52-week range
$121.05 – $219.72
96% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-132.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.45B | $14.38B | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.81B |
| Cost of revenue | $1.82B | $1.96B | $1.81B | $2.11B | $2.28B | $2.53B | $2.31B | $2.90B |
| Gross profit | $11.64B | $12.42B | $11.64B | $8.87B | $7.90B | $7.30B | $7.37B | $6.91B |
| Gross margin | 86.5% | 86.4% | 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 70.5% |
| R&D | $2.71B | $2.77B | $4.53B | $3.40B | $2.60B | $2.70B | $2.49B | $1.95B |
| Operating income | $5.89B | $7.04B | $4.59B | $2.79B | $2.89B | $2.10B | $2.49B | $1.88B |
| EBITDA | $7.01B | $7.74B | $5.11B | $3.92B | $3.54B | $2.38B | $3.00B | $3.10B |
| Net income | $4.43B | $5.89B | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| Net margin | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.2% |
| EPS (diluted) | 21.58 | 31.42 | 24.80 | 10.40 | 20.87 | 7.97 | 11.19 | 8.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $9.9B | $14.52 | $10.47–$16.50 | 16 |
| 2027 | $10.1B | $16.32 | $10.85–$19.47 | 16 |
| 2028 | $10.4B | $18.32 | $15.23–$21.05 | 5 |
| 2029 | $10.7B | $20.05 | $18.84–$21.33 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$688.36
Price
$216.06
Implied upside
+219%
Peer comparison
Biogen Inc. Common Stock
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
www.biogen.com- Employees
- 7,500
- IPO / List date
- Sep 17, 1991
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds BIIB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 203,396 | $37.3M |
| Bridgewater Associatesas of 2025-09-30 | 39,983 | $5.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BIIB yet.
